Study #2023-0665
A phase 1a/1b study investigating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the CDK4 inhibitor BGB-43395, Alone or as part of combination therapies in patients with metastatic HR+/HER2- Breast Cancer and other Advanced Solid Tumors
MD Anderson Study Status
Enrolling
Treatment Agent
BGB-43395, Fulvestrant, Letrozole
Description
This is a dose escalation and dose expansion study to compare how well BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with either fulvestrant or letrozole in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer
Study phase:
Phase I
Physician name:
Timothy Yap
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-424-0935
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.